The “HIV Antiretroviral Drug Industry Forecast” looks at past sales and reviews total world HIV Antiretroviral Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected HIV Antiretroviral Drug sales for 2023 through 2029. With HIV Antiretroviral Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV Antiretroviral Drug industry.
This Insight Report provides a comprehensive analysis of the global HIV Antiretroviral Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV Antiretroviral Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global HIV Antiretroviral Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Antiretroviral Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Antiretroviral Drug.
The global HIV Antiretroviral Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for HIV Antiretroviral Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for HIV Antiretroviral Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for HIV Antiretroviral Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key HIV Antiretroviral Drug players cover ViiV Healthcare(GlaxoSmithKline), Gilead Sciences, AbbVie Inc., Merck & Co, GSK, Bristol-Myers Squibb Company, Theratechnologies Inc., Roche Holding AG and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of HIV Antiretroviral Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Others
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ViiV Healthcare(GlaxoSmithKline)
Gilead Sciences
AbbVie Inc.
Merck & Co
GSK
Bristol-Myers Squibb Company
Theratechnologies Inc.
Roche Holding AG
Teva Pharmaceuticals
Pfizer
Frontier Biotechnologies
Shionogi
Julphar Bangladesh
Mylan Pharmaceuticals Inc.
Genentech, Inc.
Boehringer Ingelheim
Cipla
MSD
Abbott
Johnson & Johnson
Biocon Limited
Affine Formulations Limited
IPCA Laboratories
Natco Pharma
Beacon Pharmaceuticals
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global HIV Antiretroviral Drug Market Size 2018-2029
2.1.2 HIV Antiretroviral Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 HIV Antiretroviral Drug Segment by Type
2.2.1 Nucleoside Reverse Transcriptase Inhibitors
2.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
2.2.3 Protease Inhibitors
2.2.4 Fusion Inhibitors
2.2.5 Others
2.3 HIV Antiretroviral Drug Market Size by Type
2.3.1 HIV Antiretroviral Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global HIV Antiretroviral Drug Market Size Market Share by Type (2018-2023)
2.4 HIV Antiretroviral Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 HIV Antiretroviral Drug Market Size by Application
2.5.1 HIV Antiretroviral Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global HIV Antiretroviral Drug Market Size Market Share by Application (2018-2023)
3 HIV Antiretroviral Drug Market Size by Player
3.1 HIV Antiretroviral Drug Market Size Market Share by Players
3.1.1 Global HIV Antiretroviral Drug Revenue by Players (2018-2023)
3.1.2 Global HIV Antiretroviral Drug Revenue Market Share by Players (2018-2023)
3.2 Global HIV Antiretroviral Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 HIV Antiretroviral Drug by Regions
4.1 HIV Antiretroviral Drug Market Size by Regions (2018-2023)
4.2 Americas HIV Antiretroviral Drug Market Size Growth (2018-2023)
4.3 APAC HIV Antiretroviral Drug Market Size Growth (2018-2023)
4.4 Europe HIV Antiretroviral Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa HIV Antiretroviral Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas HIV Antiretroviral Drug Market Size by Country (2018-2023)
5.2 Americas HIV Antiretroviral Drug Market Size by Type (2018-2023)
5.3 Americas HIV Antiretroviral Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC HIV Antiretroviral Drug Market Size by Region (2018-2023)
6.2 APAC HIV Antiretroviral Drug Market Size by Type (2018-2023)
6.3 APAC HIV Antiretroviral Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe HIV Antiretroviral Drug by Country (2018-2023)
7.2 Europe HIV Antiretroviral Drug Market Size by Type (2018-2023)
7.3 Europe HIV Antiretroviral Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa HIV Antiretroviral Drug by Region (2018-2023)
8.2 Middle East & Africa HIV Antiretroviral Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa HIV Antiretroviral Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global HIV Antiretroviral Drug Market Forecast
10.1 Global HIV Antiretroviral Drug Forecast by Regions (2024-2029)
10.1.1 Global HIV Antiretroviral Drug Forecast by Regions (2024-2029)
10.1.2 Americas HIV Antiretroviral Drug Forecast
10.1.3 APAC HIV Antiretroviral Drug Forecast
10.1.4 Europe HIV Antiretroviral Drug Forecast
10.1.5 Middle East & Africa HIV Antiretroviral Drug Forecast
10.2 Americas HIV Antiretroviral Drug Forecast by Country (2024-2029)
10.2.1 United States HIV Antiretroviral Drug Market Forecast
10.2.2 Canada HIV Antiretroviral Drug Market Forecast
10.2.3 Mexico HIV Antiretroviral Drug Market Forecast
10.2.4 Brazil HIV Antiretroviral Drug Market Forecast
10.3 APAC HIV Antiretroviral Drug Forecast by Region (2024-2029)
10.3.1 China HIV Antiretroviral Drug Market Forecast
10.3.2 Japan HIV Antiretroviral Drug Market Forecast
10.3.3 Korea HIV Antiretroviral Drug Market Forecast
10.3.4 Southeast Asia HIV Antiretroviral Drug Market Forecast
10.3.5 India HIV Antiretroviral Drug Market Forecast
10.3.6 Australia HIV Antiretroviral Drug Market Forecast
10.4 Europe HIV Antiretroviral Drug Forecast by Country (2024-2029)
10.4.1 Germany HIV Antiretroviral Drug Market Forecast
10.4.2 France HIV Antiretroviral Drug Market Forecast
10.4.3 UK HIV Antiretroviral Drug Market Forecast
10.4.4 Italy HIV Antiretroviral Drug Market Forecast
10.4.5 Russia HIV Antiretroviral Drug Market Forecast
10.5 Middle East & Africa HIV Antiretroviral Drug Forecast by Region (2024-2029)
10.5.1 Egypt HIV Antiretroviral Drug Market Forecast
10.5.2 South Africa HIV Antiretroviral Drug Market Forecast
10.5.3 Israel HIV Antiretroviral Drug Market Forecast
10.5.4 Turkey HIV Antiretroviral Drug Market Forecast
10.5.5 GCC Countries HIV Antiretroviral Drug Market Forecast
10.6 Global HIV Antiretroviral Drug Forecast by Type (2024-2029)
10.7 Global HIV Antiretroviral Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 ViiV Healthcare(GlaxoSmithKline)
11.1.1 ViiV Healthcare(GlaxoSmithKline) Company Information
11.1.2 ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Product Offered
11.1.3 ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 ViiV Healthcare(GlaxoSmithKline) Main Business Overview
11.1.5 ViiV Healthcare(GlaxoSmithKline) Latest Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences HIV Antiretroviral Drug Product Offered
11.2.3 Gilead Sciences HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Gilead Sciences Main Business Overview
11.2.5 Gilead Sciences Latest Developments
11.3 AbbVie Inc.
11.3.1 AbbVie Inc. Company Information
11.3.2 AbbVie Inc. HIV Antiretroviral Drug Product Offered
11.3.3 AbbVie Inc. HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 AbbVie Inc. Main Business Overview
11.3.5 AbbVie Inc. Latest Developments
11.4 Merck & Co
11.4.1 Merck & Co Company Information
11.4.2 Merck & Co HIV Antiretroviral Drug Product Offered
11.4.3 Merck & Co HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Merck & Co Main Business Overview
11.4.5 Merck & Co Latest Developments
11.5 GSK
11.5.1 GSK Company Information
11.5.2 GSK HIV Antiretroviral Drug Product Offered
11.5.3 GSK HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 GSK Main Business Overview
11.5.5 GSK Latest Developments
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Information
11.6.2 Bristol-Myers Squibb Company HIV Antiretroviral Drug Product Offered
11.6.3 Bristol-Myers Squibb Company HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Bristol-Myers Squibb Company Main Business Overview
11.6.5 Bristol-Myers Squibb Company Latest Developments
11.7 Theratechnologies Inc.
11.7.1 Theratechnologies Inc. Company Information
11.7.2 Theratechnologies Inc. HIV Antiretroviral Drug Product Offered
11.7.3 Theratechnologies Inc. HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Theratechnologies Inc. Main Business Overview
11.7.5 Theratechnologies Inc. Latest Developments
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Information
11.8.2 Roche Holding AG HIV Antiretroviral Drug Product Offered
11.8.3 Roche Holding AG HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Roche Holding AG Main Business Overview
11.8.5 Roche Holding AG Latest Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Information
11.9.2 Teva Pharmaceuticals HIV Antiretroviral Drug Product Offered
11.9.3 Teva Pharmaceuticals HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Teva Pharmaceuticals Main Business Overview
11.9.5 Teva Pharmaceuticals Latest Developments
11.10 Pfizer
11.10.1 Pfizer Company Information
11.10.2 Pfizer HIV Antiretroviral Drug Product Offered
11.10.3 Pfizer HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Pfizer Main Business Overview
11.10.5 Pfizer Latest Developments
11.11 Frontier Biotechnologies
11.11.1 Frontier Biotechnologies Company Information
11.11.2 Frontier Biotechnologies HIV Antiretroviral Drug Product Offered
11.11.3 Frontier Biotechnologies HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Frontier Biotechnologies Main Business Overview
11.11.5 Frontier Biotechnologies Latest Developments
11.12 Shionogi
11.12.1 Shionogi Company Information
11.12.2 Shionogi HIV Antiretroviral Drug Product Offered
11.12.3 Shionogi HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Shionogi Main Business Overview
11.12.5 Shionogi Latest Developments
11.13 Julphar Bangladesh
11.13.1 Julphar Bangladesh Company Information
11.13.2 Julphar Bangladesh HIV Antiretroviral Drug Product Offered
11.13.3 Julphar Bangladesh HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Julphar Bangladesh Main Business Overview
11.13.5 Julphar Bangladesh Latest Developments
11.14 Mylan Pharmaceuticals Inc.
11.14.1 Mylan Pharmaceuticals Inc. Company Information
11.14.2 Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Product Offered
11.14.3 Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Mylan Pharmaceuticals Inc. Main Business Overview
11.14.5 Mylan Pharmaceuticals Inc. Latest Developments
11.15 Genentech, Inc.
11.15.1 Genentech, Inc. Company Information
11.15.2 Genentech, Inc. HIV Antiretroviral Drug Product Offered
11.15.3 Genentech, Inc. HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Genentech, Inc. Main Business Overview
11.15.5 Genentech, Inc. Latest Developments
11.16 Boehringer Ingelheim
11.16.1 Boehringer Ingelheim Company Information
11.16.2 Boehringer Ingelheim HIV Antiretroviral Drug Product Offered
11.16.3 Boehringer Ingelheim HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Boehringer Ingelheim Main Business Overview
11.16.5 Boehringer Ingelheim Latest Developments
11.17 Cipla
11.17.1 Cipla Company Information
11.17.2 Cipla HIV Antiretroviral Drug Product Offered
11.17.3 Cipla HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Cipla Main Business Overview
11.17.5 Cipla Latest Developments
11.18 MSD
11.18.1 MSD Company Information
11.18.2 MSD HIV Antiretroviral Drug Product Offered
11.18.3 MSD HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 MSD Main Business Overview
11.18.5 MSD Latest Developments
11.19 Abbott
11.19.1 Abbott Company Information
11.19.2 Abbott HIV Antiretroviral Drug Product Offered
11.19.3 Abbott HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Abbott Main Business Overview
11.19.5 Abbott Latest Developments
11.20 Johnson & Johnson
11.20.1 Johnson & Johnson Company Information
11.20.2 Johnson & Johnson HIV Antiretroviral Drug Product Offered
11.20.3 Johnson & Johnson HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Johnson & Johnson Main Business Overview
11.20.5 Johnson & Johnson Latest Developments
11.21 Biocon Limited
11.21.1 Biocon Limited Company Information
11.21.2 Biocon Limited HIV Antiretroviral Drug Product Offered
11.21.3 Biocon Limited HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 Biocon Limited Main Business Overview
11.21.5 Biocon Limited Latest Developments
11.22 Affine Formulations Limited
11.22.1 Affine Formulations Limited Company Information
11.22.2 Affine Formulations Limited HIV Antiretroviral Drug Product Offered
11.22.3 Affine Formulations Limited HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Affine Formulations Limited Main Business Overview
11.22.5 Affine Formulations Limited Latest Developments
11.23 IPCA Laboratories
11.23.1 IPCA Laboratories Company Information
11.23.2 IPCA Laboratories HIV Antiretroviral Drug Product Offered
11.23.3 IPCA Laboratories HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 IPCA Laboratories Main Business Overview
11.23.5 IPCA Laboratories Latest Developments
11.24 Natco Pharma
11.24.1 Natco Pharma Company Information
11.24.2 Natco Pharma HIV Antiretroviral Drug Product Offered
11.24.3 Natco Pharma HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 Natco Pharma Main Business Overview
11.24.5 Natco Pharma Latest Developments
11.25 Beacon Pharmaceuticals
11.25.1 Beacon Pharmaceuticals Company Information
11.25.2 Beacon Pharmaceuticals HIV Antiretroviral Drug Product Offered
11.25.3 Beacon Pharmaceuticals HIV Antiretroviral Drug Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Beacon Pharmaceuticals Main Business Overview
11.25.5 Beacon Pharmaceuticals Latest Developments
12 Research Findings and Conclusion
*If Applicable.